生产企业：LongBio Pharma
LP-005 is a first-in-class bi-functional complement antibody-fusion protein targeting both C5 and C3b, developed by LongBio Pharma. It has leading potential globally and shows therapeutic potential compared with single-target complement inhibitors.
LP-005 is a first-in-class bi-functional complement antibody-fusion protein targeting both C5 and C3b, developed by LongBio Pharma. It has leading potential globally and shows therapeutic potential compared with single-target complement inhibitors.
LP-005 is a bi-functional complement antibody-fusion protein that targets both C5 and C3b, offering a dual-target mechanism that shows therapeutic potential compared with single-target complement inhibitors.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
